Call For Abstracts – WCLC 2024
More details about WCLC 2024 abstract submission will be available in November 2023.
More details about WCLC 2024 abstract submission will be available in November 2023.
Treatment with acalabrutinib-based regimens led to long-term benefits in patients with higher-risk CLL, across all lines of therapy.
Asian Americans, Native Hawaiian, and Other Pacific Islanders
Dr Kummar discusses the significance of targeting TP53 Y220C in solid tumors and early data reported with rezatapopt in TP53 Y220C–mutant solid tumors.
An abstract is unavailable.
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible…
Apalutamide and ADT elicited a 100% biochemical recurrence-free survival rate at 24 months in high-risk localized prostate cancer following radical prostatectomy.
An abstract is unavailable.
The OncoAlert Newsletter is now out for June 23-29, 2023
Venture beyond current limits with our latest perspectives in ovarian cancer care. Learn about new treatments, improving patient outcomes.